These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
428 related articles for article (PubMed ID: 35203496)
1. CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications. Arjomandnejad M; Kopec AL; Keeler AM Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203496 [TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance. Zhang Q; Lu W; Liang CL; Chen Y; Liu H; Qiu F; Dai Z Front Immunol; 2018; 9():2359. PubMed ID: 30369931 [TBL] [Abstract][Full Text] [Related]
3. Supraphysiological FOXP3 expression in human CAR-Tregs results in improved stability, efficacy, and safety of CAR-Treg products for clinical application. Henschel P; Landwehr-Kenzel S; Engels N; Schienke A; Kremer J; Riet T; Redel N; Iordanidis K; Saetzler V; John K; Heider M; Hardtke-Wolenski M; Wedemeyer H; Jaeckel E; Noyan F J Autoimmun; 2023 Jul; 138():103057. PubMed ID: 37224732 [TBL] [Abstract][Full Text] [Related]
4. Regulatory CAR-T cells in autoimmune diseases: Progress and current challenges. Riet T; Chmielewski M Front Immunol; 2022; 13():934343. PubMed ID: 36032080 [TBL] [Abstract][Full Text] [Related]
5. The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations. Terry LV; Oo YH Front Immunol; 2020; 11():565518. PubMed ID: 33072105 [TBL] [Abstract][Full Text] [Related]
6. Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance. Muller YD; Ferreira LMR; Ronin E; Ho P; Nguyen V; Faleo G; Zhou Y; Lee K; Leung KK; Skartsis N; Kaul AM; Mulder A; Claas FHJ; Wells JA; Bluestone JA; Tang Q Front Immunol; 2021; 12():686439. PubMed ID: 34616392 [TBL] [Abstract][Full Text] [Related]
7. CAR- and TRuC-redirected regulatory T cells differ in capacity to control adaptive immunity to FVIII. Rana J; Perry DJ; Kumar SRP; Muñoz-Melero M; Saboungi R; Brusko TM; Biswas M Mol Ther; 2021 Sep; 29(9):2660-2676. PubMed ID: 33940160 [TBL] [Abstract][Full Text] [Related]
8. Membrane-bound IL-2 improves the expansion, survival, and phenotype of CAR Tregs and confers resistance to calcineurin inhibitors. Kremer J; Henschel P; Simon D; Riet T; Falk C; Hardtke-Wolenski M; Wedemeyer H; Noyan F; Jaeckel E Front Immunol; 2022; 13():1005582. PubMed ID: 36618378 [TBL] [Abstract][Full Text] [Related]
9. Treg Enhancing Therapies to Treat Autoimmune Diseases. Eggenhuizen PJ; Ng BH; Ooi JD Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977677 [TBL] [Abstract][Full Text] [Related]
10. Harnessing the inherent power of chimeric antigen receptor (CAR)-expressing regulatory T cells (CAR-Tregs) to treat autoimmune-related disorders. Kahmini FR; Shahgaldi S Mol Biol Rep; 2022 May; 49(5):4069-4078. PubMed ID: 35534581 [TBL] [Abstract][Full Text] [Related]
11. Regulatory T cell therapy: Current and future design perspectives. Rana J; Biswas M Cell Immunol; 2020 Oct; 356():104193. PubMed ID: 32823038 [TBL] [Abstract][Full Text] [Related]
12. High affinity chimeric antigen receptor signaling induces an inflammatory program in human regulatory T cells. Cochrane RW; Robino RA; Granger B; Allen E; Vaena S; Romeo MJ; de Cubas AA; Berto S; Ferreira LMR bioRxiv; 2024 Apr; ():. PubMed ID: 38617240 [TBL] [Abstract][Full Text] [Related]
13. Engineered antigen-specific regulatory T cells for autoimmune skin conditions. Mukhatayev Z; Ostapchuk YO; Fang D; Le Poole IC Autoimmun Rev; 2021 Mar; 20(3):102761. PubMed ID: 33476816 [TBL] [Abstract][Full Text] [Related]
14. Unlocking the potential of Tregs: innovations in CAR technology. Requejo Cier CJ; Valentini N; Lamarche C Front Mol Biosci; 2023; 10():1267762. PubMed ID: 37900916 [TBL] [Abstract][Full Text] [Related]
15. Tregs with an MHC class II peptide-specific chimeric antigen receptor prevent autoimmune diabetes in mice. Spanier JA; Fung V; Wardell CM; Alkhatib MH; Chen Y; Swanson LA; Dwyer AJ; Weno ME; Silva N; Mitchell JS; Orban PC; Mojibian M; Verchere CB; Fife BT; Levings MK J Clin Invest; 2023 Sep; 133(18):. PubMed ID: 37561596 [TBL] [Abstract][Full Text] [Related]